Comparative cost-effectiveness of surgery, angioplasty, or medical therapy in patients with multivessel coronary artery disease: MASS II trial.
Sara Michelly Gonçalves BrandãoPaulo Cury RezendeHans-Peter Brunner-La RoccaYang Ting JuAntonio Carlos Pedroso de LimaMyrthes Emy TakiutiWhady Armindo HuebEdimar Alcides BocchiPublished in: Cost effectiveness and resource allocation : C/E (2018)
At 5-year follow-up, the three treatment options yielded improvements in quality of life, with comparable and acceptable costs. However, despite higher initial costs, the comparison of cost-effectiveness after 5 years of follow-up among the three treatments showed both interventions (CABG and PCI) to be cost-effective strategies compared with MT.Trial registration ISRCTN, ISRCTN66068876, Registered 06/10/1994, http://www.controlled-trials.com/ISRCTN66068876.
Keyphrases
- coronary artery disease
- coronary artery bypass
- percutaneous coronary intervention
- coronary artery bypass grafting
- phase iii
- study protocol
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- phase ii
- clinical trial
- acute myocardial infarction
- acute coronary syndrome
- antiplatelet therapy
- minimally invasive
- healthcare
- cardiovascular events
- physical activity
- open label
- surgical site infection
- cardiovascular disease
- type diabetes
- heart failure
- placebo controlled
- aortic stenosis
- clinical evaluation